As of close of business last night, Editas Medicine Inc’s stock clocked out at $5.85, down -3.78% from its previous closing price of $6.08. On the day, 1331441 shares were traded.
Ratios:
To gain a deeper understanding of EDIT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.39 and its Current Ratio is at 5.39. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.
On October 18, 2023, JP Morgan Upgraded its rating to Neutral which previously was Underweight but kept the price unchanged to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when O’Neill Gilmore Neil sold 77,824 shares for $9.42 per share. The transaction valued at 732,884 led to the insider holds 327,470 shares of the business.
Mei Baisong sold 20,327 shares of EDIT for $191,425 on Mar 04 ’24. The SVP, CHIEF MEDICAL OFFICER now owns 141,543 shares after completing the transaction at $9.42 per share. On Dec 05 ’23, another insider, Eaton Bruce, who serves as the EVP, CBO AND CTO of the company, sold 103 shares for $10.90 each. As a result, the insider received 1,122 and left with 74,791 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 6.13 while its Price-to-Book (P/B) ratio in mrq is 1.37.
Stock Price History:
Over the past 52 weeks, EDIT has reached a high of $11.91, while it has fallen to a 52-week low of $5.97.
Shares Statistics:
A total of 81.77M shares are outstanding, with a floating share count of 80.80M. Insiders hold about 1.23% of the company’s shares, while institutions hold 77.98% stake in the company.
Earnings Estimates
As of right now, 14 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.67 for the current quarter, with a high estimate of -$0.44 and a low estimate of -$1.09, while EPS last year was -$0.71. The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.46 and low estimates of -$1.11.
Analysts are recommending an EPS of between -$1.84 and -$3.83 for the fiscal current year, implying an average EPS of -$2.66. EPS for the following year is -$2.74, with 15 analysts recommending between -$1.72 and -$4.51.
Revenue Estimates
In the current quarter, 12 analysts expect revenue to total $7.9M. It ranges from a high estimate of $27.5M to a low estimate of –$. As of the current estimate, Editas Medicine Inc’s year-ago sales were $9.85M, an estimated decrease of -19.80% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $6M, an increase of 43.90% over than the figure of -$19.80% in the same quarter last year. There is a high estimate of $14.7M for the next quarter, whereas the lowest estimate is –$.
A total of 15 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $78.7M, while the lowest revenue estimate was –$, resulting in an average revenue estimate of $35.66M. In the same quarter a year ago, actual revenue was $78.12M, down -54.40% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $26.48M in the next fiscal year. The high estimate is $53.86M and the low estimate is –$. The average revenue growth estimate for next year is down -25.70% from the average revenue estimate for this year.
